间苯三酚联合拉贝洛尔治疗妊娠高血压疾病的疗效研究.

Objective: To investigate the clinical effect of phloroglucin combined with labetalol in the treatment of pregnancy induced hypertension and its possible mechanisms. Methods: 180 cases of patients with hypertensive disorder complicating pregnancy who were treated in our hospital from December 2015 to December 2018, according to the order of admission, the random number table method is divided into two groups with 9 cases in each group. The control group was given phloroglucinol 200 mg intravenously for 7 days. The observation group was combined with intravenous drip of 100 mg of labetalol. When the patient's blood pressure dropped to the target period, the administration method was changed to oral labetalol tablets, 50 mg each time, three times a day, until before delivery. The outcomes of delivery (placental abruption, postpartum hemorrhage, fetal distress, cesarean section, low birth weight infants and neonatal asphyxia) and the changes of ystolic blood pressure (SBP), mean arterial pressure (MAP), diastolic blood pressure (DBP), serum cysteine protease inhibitor C (Cys-C), high mobility protein-1 (HMGB1) and homocysteine (Hcy) levels before and after treatment were compared between the two groups. Results: After treatment, the total effective rate of observation group (92.22%) was significantly higher than that of the control group (74.44%, P<0.05). The rates of placental abruption, postpartum hemorrhage, fetal distress, cesarean section, low birth weight and neonatal asphyxia in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the SBP, MAP and DBP of both groups were significantly decreased (P<0.05), which were more obvious decreased in the observation group (P<0.05). The levels of SBP, MAP and DBP, serum Hcy, HMGB1 and Cys-C in the two groups were significantly lower than those before treatment (P<0.05), and the above indicators in the observation group were significantly lower than the control group (P<0.05). Conclusion: The combination of phloroglucin and labetalol can significantly reduce the incidence of adverse delivery outcomes in pregnancy-induced hypertension and control blood pressure. The mechanism may be related to the reduction of serum Hcy, HMGB1 and Cys-C levels. [ABSTRACT FROM AUTHOR]